CARIS SCIENCE INC

SPLITOAK STRATEGIES LLC representing CARIS SCIENCE INC · Q1 2026 · $40,000 · view on lda.senate.gov ↗

Issues lobbied

MMMMedicare/Medicaid
Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing; HR 5269 RESULTS Act; HR 7148 the Consolidated Appropriations Act of 2026; updated timing of reporting under PAMA
HCRHealth Issues
Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools

Filing UUID: eab58cc6-08bc-42fe-ad60-5cb9f386efb4
Filing type: Q1
Filing period: first_quarter
Filing year: 2026
Posted: 2026-05-04T17:34:13-04:00
Registrant (lobbyist): SPLITOAK STRATEGIES LLC
Client: CARIS SCIENCE INC
Client location: TX / US
Client description: Providing precision medicine services to patients battling aggressive cancers.
Income reported: $40,000
Expenses reported: —